A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-04-27 / Trials 2019 Apr;20(1):242Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2018-11-28 / Cancers (Basel) 2018 Nov;10(12)Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-406The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
/in Breast Cancer, Glioblastoma, International Publications, Malignant Melanoma, Newcastle Disease Virus, Pancreatic Cancer /von 2018-09-26 / Cancers (Basel) 2018 Sep;10(10)Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2018-09-18 / Oncol Lett 2018 Nov;16(5):6742-6748Targeting dendritic cells in pancreatic ductal adenocarcinoma
/in Dendritic Cells, Exosome, International Publications, Pancreatic Cancer /von 2018-06-18 / Cancer Cell Int. 2018;18:85WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2018-04-01 / Anticancer Res. 2018 04;38(4):2217-2225Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2018-02-25 / Integr Cancer Ther 2018 09;17(3):994-999Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
/in International Publications, Pancreatic Cancer /von 2017-12-01 / Ann. Oncol. 2017 Dec;28(12):2950-2961
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de